K4 Elite
K4 Elite
A synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, studied for T-cell maturation signaling, MHC class II binding and immune modulation in rodent tumour and immunosuppression models.
Thymopentin is the pentapeptide Arg-Lys-Asp-Val-Tyr (RKDVY), corresponding to positions 32 through 36 of thymopoietin, a 49-residue thymic polypeptide. It was identified as the shortest fragment retaining the immunomodulatory activity attributed to the parent molecule [3][6].
The peptide is a long-standing tool in thymic and T-cell biology and has been used clinically in several jurisdictions in immunodeficiency settings, which means its literature spans four decades of both mechanistic and clinical reporting [6].
A recurring theme in the modern research record is its very short plasma half-life, which has driven a substantial body of formulation and conjugate chemistry work - PEGylated niosomes, alginic acid protection of the N-terminus, and hybrid peptide constructs - aimed at extending exposure in animal models [4][5].
Mechanistic work describes thymopentin binding to MHC class II (HLA-DR) molecules, and molecular analyses of that interaction have been used to propose how a five-residue peptide can influence antigen-presentation-linked signaling [1]. The literature associates the peptide with T-cell maturation and with restoration of thymic architecture in models of induced thymic atrophy [2].
Downstream reports describe modulation of T-cell subset distribution, cytokine output and macrophage phenotype in tumour-bearing and immunosuppressed animals. Because the peptide is rapidly cleared, much of the recent mechanistic work is performed with stabilized derivatives rather than the free pentapeptide, which is a documented interpretive limitation [4][5].
Investigators established an H22 tumour-bearing mouse model to test whether water-soluble alginic acid conjugation protects the N-terminus of TP5. Readouts were thymus, spleen and liver indices, immune cell activity assays and cytokine levels, compared against unmodified peptide and untreated controls [4].
A study of thymic rejuvenation evaluated thymopentin across several syngeneic murine tumour models - B16-F10 melanoma, MC38 colorectal carcinoma, Hepa 1-6 and LM3 hepatocellular carcinoma - measuring thymic architecture, T-cell subset composition and functional markers, and reporting relief of immunosuppression in tumour-bearing animals relative to controls [2].
Work published in Communications Medicine combined thymopentin with adenoviral oncolytic therapy in a murine model and used flow cytometry of tumour-infiltrating macrophages and CD8+ T cells as the primary mechanistic measure [3].
Molecular analysis of thymopentin binding to HLA-DR molecules used binding assays and structural modelling to characterize the interaction between the pentapeptide and class II MHC [1].
Earlier clinical reporting compiled several short- and long-term studies of the pentapeptide in rheumatoid arthritis cohorts, and a separate study reported changes in clinical parameters and lymphocyte subpopulations in atopic dermatitis [6][7].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.